Drug Information
Drug Generic Name | ESOMEPRAZOLE |
Drug Class | PROTON PUMP INHIBITORS |
Chapter | Gastrointestinal System |
Suppresses gastric acid secretion by blocking proton pump within gastric parietal cells. Indications: gastroesophageal reflux disease (GERD), duodenal ulcer associated with Helicobacter pylori in combination with amoxicillin and clarithromycin or metronidazole, gastric ulcers associated with continuous NSAID therapy. Cautions: Used with caution in patients with liver disease, in pregnancy, breast- feeding and it may mask the symptoms of gastric cancer. Side effect: Flatulence; abdominal pain, dyspepsia, nausea; vomiting, diarrhoea, dry mouth; constipation; Headache; dizziness. Less frequent side effects include dry mouth, insomnia, drowsiness, malaisa, blurred vision, rash, and pruritus and dermatitis. Dose: By mouth duodenal ulcer associated with Helicobacter pylori 20 mg twice daily for 2 weeks in combination with amoxicillin, 1000 mg twice daily and clarithromycin 500mg twice daily or metronidazole 400 mg twice daily, NSAID- associated gastric ulcer, 20 mg once daily for 4- 8 weeks; Prophylaxis in patients with an increased risk of gastroduodenal complications who required continued NSAID treatment, 20 mg daily. Gastro- 0esophaeal reflux disease, 40 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist, maintenance 20 mg daily, symptomatic treatment in the absence of oesophagitis, 20 mg daily for up 4 weeks, then 20 mg daily when required. Not recommended in children. By intravenous injection over at least 3 minutes or by intravenous infusion, gastro-oesophageal reflux disease, 40 mg once daily, symtomatic reflux disease without oesopgagitis, treatment of NSAID- associated gastric ulcer, prevention, of NSAID-associated gastric or duodenal ulcer, 20 mg daily, continue until oral administration possible.. |
|
Brand Name |
|